Overview
Biodesix provides advanced blood-based diagnostic tests for lung cancer risk assessment and treatment guidance, including Nodify Lung, GeneStrat, and VeriStrat tests. They offer custom development services to biopharmaceutical and life sciences companies for therapeutic clinical trials, diagnostic validation, and commercialization of IVD and LDT tests. Their AI and machine learning capabilities support personalized care and early lung cancer detection.
Frequently asked questions
- What diagnostic tests does Biodesix offer for lung cancer?
- Biodesix offers Nodify Lung for pulmonary nodule risk assessment, GeneStrat and GeneStrat NGS for tumor mutation testing in NSCLC, and VeriStrat for immunotherapy guidance.
- What development services are available for pharma and life sciences?
- Biodesix provides custom services to enable therapeutic clinical trials, validate diagnostics and life sciences tools, and develop/commercialize novel diagnostics, including specimen kitting and high-throughput molecular testing.
- What regulatory validations has Biodesix achieved?
- Biodesix validated Thermo Fisher's Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer, contributing to its FDA approval.